Guarding the frontiers: the biology of type III interferons

Type III interferons (IFNs) or IFN-λs regulate a similar set of genes as type I IFNs, but whereas type I IFNs act globally, IFN-λs primarily target mucosal epithelial cells and protect them against the frequent viral attacks that are typical for barrier tissues. IFN-λs thereby help to maintain healthy mucosal surfaces through immune protection, without the significant immune-related pathogenic risk associated with type I IFN responses. Type III IFNs also target the human liver, with dual effects: they induce an antiviral state in hepatocytes, but specific IFN-λ4 action impairs the clearance of hepatitis C virus and could influence inflammatory responses. This constitutes a paradox that has yet to be resolved.

[1]  Steven H Kleinstein,et al.  Dynamic expression profiling of type I and type III interferon‐stimulated hepatocytes reveals a stable hierarchy of gene expression , 2014, Hepatology.

[2]  J. Renauld,et al.  Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. , 2004, The Journal of biological chemistry.

[3]  K. Yui.  Cross-presentation of malaria antigen by brain microvessels: why CD8+ T cells are critical for the pathogenesis of experimental cerebral malaria , 2013, EMBO molecular medicine.

[4]  G. Gallagher,et al.  Regulation of interferon lambda-1 (IFNL1/IFN-λ1/IL-29) expression in human colon epithelial cells. , 2014, Cytokine.

[5]  M. Wadhwa,et al.  Biological activity of interleukins-28 and -29: comparison with type I interferons. , 2005, Cytokine.

[6]  J. Hiscott,et al.  Gene Expression and Antiviral Activity of Alpha/Beta Interferons and Interleukin-29 in Virus-Infected Human Myeloid Dendritic Cells , 2005, Journal of Virology.

[7]  L. Lenz,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[8]  Thomas Berg,et al.  IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy , 2009, Nature Genetics.

[9]  G. Kochs,et al.  Temporal and Spatial Resolution of Type I and III Interferon Responses In Vivo , 2010, Journal of Virology.

[10]  D. Tough,et al.  Interferon‐β and interferon‐λ signaling is not affected by interferon‐induced refractoriness to interferon‐α in vivo , 2011, Hepatology.

[11]  S. Paludan,et al.  Interferon-λ Is Functionally an Interferon but Structurally Related to the Interleukin-10 Family* , 2009, The Journal of Biological Chemistry.

[12]  R. Rabin,et al.  Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent , 2012, Immunology and cell biology.

[13]  A. Lewis-Antes,et al.  IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex , 2003, Nature Immunology.

[14]  P. Desmond,et al.  Does IL28B genotyping still have a role in the era of direct‐acting antiviral therapy for chronic hepatitis C infection? , 2012, Journal of viral hepatitis.

[15]  M. Diamond,et al.  Commensal microbes and interferon-λ determine persistence of enteric murine norovirus infection , 2015, Science.

[16]  M. Albert,et al.  Type I and Type III Interferons Drive Redundant Amplification Loops to Induce a Transcriptional Signature in Influenza-Infected Airway Epithelia , 2013, PLoS pathogens.

[17]  P. Cossart,et al.  Diverse intracellular pathogens activate Type III Interferon expression from peroxisomes , 2014, Nature Immunology.

[18]  P. Lampertico,et al.  Peginterferon-α does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. , 2012, Journal of hepatology.

[19]  T. Michiels,et al.  Human but Not Mouse Hepatocytes Respond to Interferon-Lambda In Vivo , 2014, PloS one.

[20]  A. Boonstra,et al.  IFN‐λ‐mediated IL‐12 production in macrophages induces IFN‐γ production in human NK cells , 2015, European journal of immunology.

[21]  S. Johnston,et al.  Interferon-lambda as a new approach for treatment of allergic asthma? , 2011, EMBO molecular medicine.

[22]  S. Smirnov,et al.  Lambda Interferon Is the Predominant Interferon Induced by Influenza A Virus Infection In Vivo , 2010, Journal of Virology.

[23]  E. Coccia,et al.  Viral infection and Toll‐like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte‐derived dendritic cells , 2004, European journal of immunology.

[24]  D. Booth,et al.  Will IL28B polymorphisms remain relevant to direct-acting antiviral treatment paradigms? , 2012, Antiviral therapy.

[25]  G. Lutfalla,et al.  Interferon-λ is functionally an interferon but structurally related to the IL-10 family , 2009 .

[26]  K. Shuai,et al.  UBP43 is a novel regulator of interferon signaling independent of its ISG15 isopeptidase activity , 2006, The EMBO journal.

[27]  H. Günthard,et al.  The IFNL3/4 &Dgr;G variant increases susceptibility to cytomegalovirus retinitis among HIV-infected patients , 2014, AIDS.

[28]  T. Pietschmann,et al.  Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses , 2013, The EMBO journal.

[29]  Raymond T Chung,et al.  Kinetic differences in the induction of interferon stimulated genes by interferon‐α and interleukin 28B are altered by infection with hepatitis C virus , 2014, Hepatology.

[30]  M. Callanan,et al.  Lymphocytes degranulation in liver in hepatitis C virus carriers is associated with IFNL4 polymorphisms and ALT levels. , 2014, The Journal of infectious diseases.

[31]  Barbara Rehermann,et al.  A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus , 2013, Nature Genetics.

[32]  F. Barré-Sinoussi,et al.  Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. , 2009, The Journal of clinical investigation.

[33]  M. Shiffman,et al.  Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection , 2010, Hepatology.

[34]  S. Kotenko,et al.  Interferon induction and function at the mucosal surface , 2013, Immunological reviews.

[35]  T. Graeber,et al.  Type I Interferon Suppresses Type II Interferon–Triggered Human Anti-Mycobacterial Responses , 2013, Science.

[36]  Colin W Shepard,et al.  Global epidemiology of hepatitis C virus infection. , 2005, The Lancet. Infectious diseases.

[37]  K. Hartshorn,et al.  Differentiated Human Alveolar Type II Cells Secrete Antiviral IL-29 (IFN-λ1) in Response to Influenza A Infection1 , 2009, The Journal of Immunology.

[38]  C. O’Farrelly,et al.  Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection , 2011, Proceedings of the National Academy of Sciences.

[39]  J. Nattermann,et al.  Do λ-IFNs IL28A and IL28B act on human natural killer cells? , 2011, Proceedings of the National Academy of Sciences.

[40]  Z. Kutalik,et al.  Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[41]  A. Sher,et al.  Type I interferons in infectious disease , 2015, Nature Reviews Immunology.

[42]  A. Koike,et al.  Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C , 2009, Nature Genetics.

[43]  Sophia Davidson,et al.  Pathogenic potential of interferon αβ in acute influenza infection , 2014, Nature Communications.

[44]  A. Iwasaki,et al.  Epigenetic Reprogramming of the Type III Interferon Response Potentiates Antiviral Activity and Suppresses Tumor Growth , 2014, PLoS biology.

[45]  L. Kaderali,et al.  Transcriptome analysis reveals a classical interferon signature induced by IFNλ4 in human primary cells , 2015, Genes and Immunity.

[46]  S. Günther,et al.  Lambda Interferon Renders Epithelial Cells of the Respiratory and Gastrointestinal Tracts Resistant to Viral Infections , 2010, Journal of Virology.

[47]  M. Dennis,et al.  Selection on a Variant Associated with Improved Viral Clearance Drives Local, Adaptive Pseudogenization of Interferon Lambda 4 (IFNL4) , 2014, PLoS genetics.

[48]  A. Muir.  IL28B in the era of direct-acting antivirals for hepatitis C. , 2013, Journal of clinical gastroenterology.

[49]  B. A. Fox,et al.  The Role of Genomic Data in the Discovery, Annotation and Evolutionary Interpretation of the Interferon-Lambda Family , 2009, PloS one.

[50]  A. Sher,et al.  Intranasal Poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. , 2010, The Journal of clinical investigation.

[51]  Maxim N. Artyomov,et al.  Interferon-λ cures persistent murine norovirus infection in the absence of adaptive immunity , 2015, Science.

[52]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[53]  M. Hornef,et al.  IFN-λ determines the intestinal epithelial antiviral host defense , 2011, Proceedings of the National Academy of Sciences.

[54]  T. Michiels,et al.  Interferon-λ in the Context of Viral Infections: Production, Response and Therapeutic Implications , 2014, Journal of Innate Immunity.

[55]  S. Paludan,et al.  Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. , 2006, The Journal of general virology.

[56]  Charles M. Rice,et al.  Interferons α and λ Inhibit Hepatitis C Virus Replication With Distinct Signal Transduction and Gene Regulation Kinetics , 2006 .

[57]  S. Kotenko,et al.  Interferon-lambda: a new addition to an old family. , 2010, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[58]  G. Gallagher,et al.  IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. , 2009, Blood.

[59]  S. Johnston,et al.  Respiratory virus induction of alpha‐, beta‐ and lambda‐interferons in bronchial epithelial cells and peripheral blood mononuclear cells , 2009, Allergy.

[60]  A. Lewis-Antes,et al.  Type III IFNs Are Produced by and Stimulate Human Plasmacytoid Dendritic Cells , 2012, The Journal of Immunology.

[61]  Jacques Fellay,et al.  IL28B genotype is associated with differential expression of intrahepatic interferon‐stimulated genes in patients with chronic hepatitis C , 2010, Hepatology.

[62]  R. Geffers,et al.  Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential , 2013, mBio.

[63]  S. Kotenko,et al.  The role of transposable elements in the regulation of IFN-λ1 gene expression , 2009, Proceedings of the National Academy of Sciences.

[64]  E. Flaño,et al.  Toll-Like Receptor Expression and Induction of Type I and Type III Interferons in Primary Airway Epithelial Cells , 2013, Journal of Virology.

[65]  S. Pellegrini,et al.  USP18-Based Negative Feedback Control Is Induced by Type I and Type III Interferons and Specifically Inactivates Interferon α Response , 2011, PloS one.

[66]  B. Aronow,et al.  Blockade of Chronic Type I Interferon Signaling to Control Persistent LCMV Infection , 2013, Science.

[67]  Scott R. Presnell,et al.  IL-28, IL-29 and their class II cytokine receptor IL-28R , 2002, Nature Immunology.

[68]  G. Gallagher,et al.  Regulation of IFN-λ1 Promoter Activity (IFN-λ1/IL-29) in Human Airway Epithelial Cells , 2011, The Journal of Immunology.

[69]  T. Michiels,et al.  IFN-Lambda (IFN-λ) Is Expressed in a Tissue-Dependent Fashion and Primarily Acts on Epithelial Cells In Vivo , 2008, PLoS pathogens.

[70]  T. Liang,et al.  Association of IL28B genotype with fibrosis progression and clinical outcomes in patients with chronic hepatitis C: A longitudinal analysis , 2013, Hepatology.

[71]  P. Staeheli,et al.  Leukocyte-Derived IFN-α/β and Epithelial IFN-λ Constitute a Compartmentalized Mucosal Defense System that Restricts Enteric Virus Infections , 2015, PLoS pathogens.

[72]  Sven Bergmann,et al.  Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. , 2010, Gastroenterology.

[73]  C. Brander,et al.  Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. , 2013, Journal of hepatology.

[74]  A. Craxì,et al.  IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease. , 2012, Journal of hepatology.

[75]  Pallavur Sivakumar,et al.  Interleukin‐29 uses a type 1 interferon‐like program to promote antiviral responses in human hepatocytes , 2006, Hepatology.

[76]  L. Prokunina-Olsson,et al.  IFNL4-ΔG genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with sofosbuvir and ribavirin. , 2014, The Journal of infectious diseases.

[77]  Jonathan L. Schmid-Burgk,et al.  Control of Hepatitis C Virus Replication in Mouse Liver-Derived Cells by MAVS-Dependent Production of Type I and Type III Interferons , 2015, Journal of Virology.

[78]  M. Neurath,et al.  IL-28A (IFN-λ2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease , 2011, EMBO molecular medicine.

[79]  F. Souza-Fonseca-Guimaraes,et al.  NK cells require IL-28R for optimal in vivo activity , 2015, Proceedings of the National Academy of Sciences.

[80]  A. Wlodawer,et al.  Crystal Structure of Human Interferon-λ1 in Complex with Its High-Affinity Receptor Interferon-λR1 , 2010, Journal of Molecular Biology.

[81]  Judith N. Mandl,et al.  Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections , 2008, Nature Medicine.

[82]  David B. Goldstein,et al.  Genetic variation in IL28B and spontaneous clearance of hepatitis C virus , 2009, Nature.

[83]  S. Kotenko,et al.  IFN Regulatory Factor Family Members Differentially Regulate the Expression of Type III IFN (IFN-λ) Genes1 , 2007, The Journal of Immunology.

[84]  S. Akira,et al.  Viral Infections Activate Types I and III Interferon Genes through a Common Mechanism* , 2007, Journal of Biological Chemistry.

[85]  S. Paludan,et al.  Lambda Interferon (IFN-λ), a Type III IFN, Is Induced by Viruses and IFNs and Displays Potent Antiviral Activity against Select Virus Infections In Vivo , 2006, Journal of Virology.

[86]  A. Sher,et al.  Influenza A Virus Impairs Control of Mycobacterium tuberculosis Coinfection Through a Type I Interferon Receptor–Dependent Pathway , 2013, The Journal of infectious diseases.

[87]  V. Wong,et al.  Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease , 2015, Nature Communications.

[88]  R. Schreiber,et al.  Persistent LCMV Infection Is Controlled by Blockade of Type I Interferon Signaling , 2013, Science.

[89]  I. Udalova,et al.  IFN-λ resolves inflammation via suppression of neutrophil infiltration and IL-1β production , 2015, The Journal of experimental medicine.

[90]  U. Jensen,et al.  An Important Role for Type III Interferon (IFN-λ/IL-28) in TLR-Induced Antiviral Activity1 , 2008, The Journal of Immunology.

[91]  N. Mueller,et al.  Influence of IFNL3/4 polymorphisms on the incidence of cytomegalovirus infection after solid-organ transplantation. , 2015, The Journal of infectious diseases.

[92]  Christian A. Luber,et al.  Mouse CD8α+ DCs and human BDCA3+ DCs are major producers of IFN-λ in response to poly IC , 2010, The Journal of experimental medicine.

[93]  G. Gallagher,et al.  Modulation of human plasmacytoid DC function by IFN‐λ1 (IL‐29) , 2009, Journal of leukocyte biology.

[94]  田原 康玄,et al.  生活習慣病とgenome-wide association study , 2015 .

[95]  M. Buti,et al.  Faldaprevir and deleobuvir for HCV genotype 1 infection. , 2013, The New England journal of medicine.

[96]  Z. Kutalik,et al.  Correction: Corrigendum: Reduced IFNλ4 activity is associated with improved HCV clearance and reduced expression of interferon-stimulated genes , 2014, Nature Communications.

[97]  T. Hassanein,et al.  A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. , 2014, Journal of hepatology.

[98]  J. Casanova,et al.  Evolutionary genetic dissection of human interferons , 2011, The Journal of experimental medicine.

[99]  J. Renauld,et al.  Interferon-λ Contributes to Innate Immunity of Mice against Influenza A Virus but Not against Hepatotropic Viruses , 2008, PLoS pathogens.

[100]  Orland R. Gonzalez,et al.  A Systematic Analysis of Host Factors Reveals a Med23-Interferon-λ Regulatory Axis against Herpes Simplex Virus Type 1 Replication , 2013, PLoS pathogens.

[101]  M. Battegay,et al.  IL-28B is a Key Regulator of B- and T-Cell Vaccine Responses against Influenza , 2014, PLoS pathogens.

[102]  Katherine R. Smith,et al.  Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort , 2011, Genome Medicine.

[103]  A. Nielsen,et al.  Type III Interferon (IFN) Induces a Type I IFN-Like Response in a Restricted Subset of Cells through Signaling Pathways Involving both the Jak-STAT Pathway and the Mitogen-Activated Protein Kinases , 2007, Journal of Virology.

[104]  Z. Kutalik,et al.  IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non‐1 HCV genotypes , 2012, Hepatology.

[105]  A. C. Looman,et al.  Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines , 2009, Genes and Immunity.

[106]  A. Wlodawer,et al.  Crystal structure of the complex of human interferon-lambda1 with its high affinity receptor interferon-lambdaR1. , 2010 .

[107]  J. Carlis,et al.  Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. , 2009, The Journal of clinical investigation.

[108]  Dylan J. Taatjes,et al.  The Mediator complex and transcription regulation , 2013, Critical reviews in biochemistry and molecular biology.

[109]  A. Boonstra,et al.  IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNγ receptor expression. , 2011, Blood.

[110]  Sophia Davidson,et al.  Disease-Promoting Effects of Type I Interferons in Viral, Bacterial, and Coinfections , 2015, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[111]  Albert C. Huang,et al.  Interferon-λ restricts West Nile virus neuroinvasion by tightening the blood-brain barrier , 2015, Science Translational Medicine.

[112]  S. Kotenko,et al.  Usp18 deficient mammary epithelial cells create an antitumour environment driven by hypersensitivity to IFN-λ and elevated secretion of Cxcl10 , 2013, EMBO molecular medicine.

[113]  M. Seldin,et al.  The Cumulative Effects of Known Susceptibility Variants to Predict Primary Biliary Cirrhosis Risk , 2015, Genes and Immunity.

[114]  Rekha Menon,et al.  Child Nutrition, Child Health, and School Enrollment: A Longitudinal Analysis , 1997 .

[115]  N. Hacohen,et al.  Peroxisomes Are Signaling Platforms for Antiviral Innate Immunity , 2010, Cell.